Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%. Here's what Shoenhaus could be thinking will catalyze a reversal for this stock. An intriguing new development may take a long time to pay off In January, Recursion made an interesting decision regarding one of the assets it's developing in its fibrotic disease collaboration with Bayer While the biotech's bread and butter is collaboration revenue right now -- as it has no medicines on the market of its own -- it opted to in-license one of its preclinical candidates under co-development, such that it would have the full rights to any therapies the program leads to. That means it won't get that portion of the collaboration income, and also that it coughed up an undisclosed amount of cash for the privilege of full ownership. The company currently only has $392 million in cash, equivalents, and short-term investments, and it
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Where Will Recursion Pharmaceuticals Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewswire
- Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/27/24 - Beat
RXRX
Sec Filings
- 4/25/24 - Form 3
- 4/25/24 - Form 144
- 4/23/24 - Form ARS
- RXRX's page on the SEC website